The safety and efficacy of low dose BCG intravesical instillation for the treatment of uremic or kidney transplant patients with recurrent urothelial carcinoma of the bladder

Abstract

RFA. In this cohort, local recurrence-free survival (p 1⁄4 0.76) and metastases-free survival (p 1⁄4 0.51) were similar between PN and RFA. In both the cT1a and cT1b groups, PN patients were significantly younger, with lower Charlson scores and had superior overall survival (p < 0.001 for all). In the RFA group, all patients have been biopsy before RFA and 22 been proved RCC. The number of RFA needle treatment were significantly correlated to PADUA score. 13 patients were under local anesthesia, the other were under IVGA by anesthesiologist. Only one patient presented mild pneumothorax after RFA without intervention treatment. Renal function deterioration after procedure did not reveal clinical significance. Tumor recurrence was recognized by CT scan in 3 patients during followup, who repeated RFA treatment without recurrence. CONCLUSIONS: For carefully selected patients, RFA represent a less invasive alternative associated with less morbidity and fewer complications and a promising treatment compared with partial nephrectomy. However, the long-term efficacy of these approaches remains to be established.